Kalaris Therapeutics, Inc.

KLRS▼

Abbott Cooper PLLC Investigates Kalaris Therapeutics Board for Potential Fiduciary Breaches

Abbott Cooper PLLC has launched an investigation into potential legal claims on behalf of Kalaris Therapeutics, Inc. stockholders. The investigation focuses on whether the board of directors of Kalaris Therapeutics, formerly known as AlloVir, Inc., breached their fiduciary duties. Stockholders who have continuously held shares since prior to November 7, 2024, are encouraged to contact the firm at no cost or obligation. Abbott Cooper PLLC handles cases on a contingency fee basis, meaning stockholders incur no cost unless a recovery is obtained.

KLRS ▼

GlobeNewswire·46dRead more →

KLRS

Kalaris Therapeutics appoints Liisa Bayko as CFO

Kalaris Therapeutics has appointed Liisa Bayko as chief financial officer. Bayko brings more than two decades of experience in biotechnology finance, strategy, and capital markets, most recently serving as managing director and senior biotechnology analyst at Evercore ISI. Shares of Kalaris Therapeutics fell 5.25 percent to $4.15 in pre-market trading.

KLRS

Seeking Alpha·60dRead more →

KLRS▲3

Kalaris Therapeutics Reports Positive Phase 1a Results for TH103 in Neovascular AMD

Kalaris Therapeutics announced encouraging additional data from its Phase 1a single ascending dose trial of TH103 in neovascular age-related macular degeneration. The expanded dataset included 17 treatment-naive patients and 3 treatment-experienced patients, all completing six months of follow-up, and showed robust improvements in vision and retinal anatomy. Pharmacokinetic data indicated 27- to 53-fold lower plasma Cmax compared to leading anti-VEGF agents, suggesting greater intraocular retention, with 41% of treatment-naïve patients requiring retreatment at 4 months or later, 35% at 5 months or later, and 29% needing no additional anti-VEGF therapy during the six-month follow-up. Treatment-experienced patients saw an average two-month extension in retreatment intervals compared with prior therapies. No cases of intraocular inflammation were observed at the 2.5 mg dose following manufacturing process adjustments, while one patient at the 5 mg dose experienced transient intraocular inflammation that resolved without sequelae.

KLRS ▲

RTTNews·63dRead more →